What Is Avalo Therapeutics, Inc. (AVTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Avalo Therapeutics, Inc.'s intrinsic value is estimated at $4.72, suggesting the stock is overvalued at its current price of $18.55. With 8 out of 9 models flagging downside (-74.5% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: PWERM targets $19.30 (+4.1%), versus Sentiment SOTP at $0.47 (-97.4%). This +101.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About AVTX?
9 of 13 models are currently active for AVTX. Of these, 1 model suggests upside while 8 models suggest overvaluation. The Bayesian DCF estimates AVTX's intrinsic value at $6.30, implying -66.1% downside from the current price. See which stocks rank higher →
How Does AVTX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, AVTX ranks #336 by Quality of Company score. CirclFi's QOC score of 4.0/10 evaluates 32 fundamental signals. A score of 4.0 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Avalo Therapeutics, Inc. competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is AVTX a Value Trap?
CirclFi's Value Trap algorithm assigns AVTX a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Avalo Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Avalo Therapeutics, Inc. is rated at 4.0/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +101.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every AVTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across AVTX's 9 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad